Compare Trade Desk Inc (TTD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trade Desk Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Trade Desk Inc trades at $18.27 (market cap $8.76B), while Vertex Pharmaceuticals Incorporated trades at $478.06 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 13.9× Trade Desk Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| TTD | VRTX | |
|---|---|---|
Market Cap | $8.76B | $121.95B |
Sector | Technology | Health |
52-Week High | $89.76 | $529.59 |
52-Week Low | $17.33 | $366.54 |
Enterprise Value | $7.78B | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Trade Desk (TTD) trades at $18.25, down 1.83% with bearish technical signals. Revenue grew to $2.9B in 2025 with strong 77.8% gross margins, though Q1 2026 EPS missed expectations. Recent executive appointments and the Publicis dispute settlement provide operational stability. The stock faces headwinds from slowing growth and competitive pressure from tech giants.
TTD presents a value opportunity at 21x P/E with 49% analyst buy ratings and $25.23 price target upside. Risks include persistent revenue deceleration and market share loss to walled gardens. The company's profitability and strategic partnerships support long-term potential despite near-term challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
